认证与非认证静脉中心腔内消融治疗患者管理与结局差异显著
本研究采用匹配对照设计,基于美国两大静脉注册登记数据,比较2015至2018年间192个中心共39001例接受腔内消融患者的结局与利用指数。结果显示认证中心更倾向于治疗晚期静脉疾病患者,非认证中心高利用指数比例更高,认证中心并发症略低但1年随访率更低,而静脉临床严重程度评分改善更明显。
要点
- 认证中心更可能治疗晚期静脉疾病(C4-C6:38.1% vs 25.2%,P < .001)。
- 非认证中心高利用指数(3.4)患者比例更高(3.3% vs 0.1%,P < .001)。
- 认证中心并发症更低(0.1% vs 0.4%,P < .001)但1年随访率更低(31.5% vs 76.4%)。
核心结论
- 静脉注册登记是识别低风险手术利用率和并发症显著差异的有力工具。
- 认证与腔内治疗使用减少、并发症略低、1年随访率更低及静脉临床严重程度评分改善更大相关。
研究设计与样本
- 匹配对照设计,使用前瞻性收集的美国血管外科协会血管质量倡议静脉曲张注册登记和美国静脉与淋巴学会PRO静脉注册登记数据。
- 共纳入2015至2018年间192个中心的39001例患者,其中血管质量倡议静脉曲张注册登记19810例(50.8%),PRO静脉注册登记19191例(49.2%)。
主要发现
- 认证中心治疗晚期静脉疾病(C4-C6)患者比例显著高于非认证中心(38.1% vs 25.2%,P < .001)。
- 非认证中心治疗的高利用指数(2个标准差以上,即3.4利用指数)患者比例显著更高(3.3% vs 0.1%,P < .001)。
- 消融后1个月至1年评估的静脉临床严重程度评分在非认证中心下降4.98 ± 4.01,认证中心下降5.61 ± 3.64(P < .001)。
- 并发症发生率非认证中心为71例(0.4%),认证中心为17例(0.1%)(P < .001)。
- 1年临床随访率非认证中心为76.4%,认证中心为31.5%(P < .001)。
临床怎么用
- 认证状态与更严格的腔内治疗使用和略低的并发症相关,可考虑作为质量改进的参考。
- 认证中心1年随访率较低,需关注术后随访管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Intersocietal Accreditation Commission of vein centers was instituted in 2014, yet data regarding impact of accreditation on patients undergoing superficial vein interventions are lacking. This study was undertaken to identify differences in patient outcomes and utilization index as a measure of appropriate use in accredited compared with nonaccredited centers. METHODS: This study was performed with a matched control design using prospectively collected data from two major U.S.-based venous registries: the Society for Vascular Surgery Vascular Quality Initiative Varicose Vein Registry and the American Vein & Lymphatic Society PRO Venous Registry. RESULTS: A total of 39,001 patients treated between 2015 and 2018 in 192 centers were included in the study. The Vascular Quality Initiative Varicose Vein Registry provided information on 19,810 (50.8%) patients, and the American Vein & Lymphatic Society PRO Venous Registry provided information on 19,191 (49.2%) patients. Accredited centers were significantly more likely to treat patients with advanced venous disease as characterized by trophic skin changes (C4-C6, 38.1% vs 25.2%; P < .001). Percentage of patients treated 2 standard deviations above the Medicare-reported mean (3.4 utilization index) was significantly higher among patients treated at nonaccredited centers (3.3% vs 0.1%; P < .001). Venous Clinical Severity Score of those who were assessed between 1 month and 1 year after ablation decreased by 4.98 ± 4.01 in nonaccredited centers compared with 5.61 ± 3.64 in accredited centers (P < .001). Complications were low in both cohorts (nonaccredited centers, 71 [0.4%]; accredited centers, 17 [0.1%]; P < .001). One-year clinical follow-up was higher in nonaccredited centers (76.4% vs 31.5%; P < .001). CONCLUSIONS: Venous registries are a powerful tool for capturing and identifying significant variations in procedure utilization and complications in low-risk procedures. Intersocietal Accreditation Commission accreditation was associated with reduced use of endovenous therapies, slightly lower complication rates, lower 1-year follow up, and greater improvement in Venous Clinical Severity Score.
引用
- Obi AT, Afridi S, Lurie F, et al. Management and treatment outcomes of patients undergoing endovenous ablation are significantly different between Intersocietal Accreditation Commission-accredited and nonaccredited vein centers. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32721587. doi:10.1016/j.jvsv.2020.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。